About Hualin Xi
Hualin Xi, who goes by Simon Xi, co-founded Rgenta Therapeutics and is its chief executive officer and a director. He has held that role since the company launched in April 2020. Rgenta develops oral, small-molecule medicines that target RNA to treat cancer and neurological diseases that current drugs cannot reach.
He has announced several funding rounds and partnerships as Rgenta's chief executive officer. These include a $20 million seed round in April 2020 and a research collaboration with H. Lundbeck A/S in August 2021. Rgenta also raised a $52 million Series A round in November 2022.
Experience
This experience comes from official bios and from SEC filings. For roles taken from filings, the years are when the filings name Hualin Xi in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Hualin Xi works with at each company, as listed on that company's latest Form D.
Hualin Xi in the News
Sources
- SECRgenta Therapeutics, Inc. Form D, filed Nov 3, 2026
- press releaseRgenta Therapeutics Raises $52M in Series A Financing (PR Newswire)
- press releaseRgenta Therapeutics Enters into a Collaboration with Lundbeck (PR Newswire)
- press releaseRgenta Therapeutics Launches with $20 Million Seed Investment (PR Newswire)
- journal articlePFRED: A computational platform for siRNA and antisense oligonucleotides design (PMC)